50 related articles for article (PubMed ID: 38603651)
1. Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Connolly RM; Wang V; Hyman DM; Grivas P; Mitchell EP; Wright JJ; Sharon E; Gray RJ; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Wang J; Wisinski KB; Tricoli JV; Conley BA; Harris LN; Arteaga CL; O'Dwyer PJ; Chen AP; Flaherty KT
Clin Cancer Res; 2024 Apr; 30(7):1273-1280. PubMed ID: 38433347
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.
Garmezy B; Borad MJ; Bahleda R; Perez CA; Chen LT; Kato S; Oh DY; Severson P; Tam BY; Quah CS; Harding JJ
Cancer Res Commun; 2024 Apr; 4(4):1165-1173. PubMed ID: 38602417
[TBL] [
